XML 53 R42.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue Recognition - Nature of Goods and Services (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2025
USD ($)
segment
agreement
Mar. 31, 2024
USD ($)
segment
Dec. 31, 2024
Revenue Recognition [Line Items]      
Number of operating segments | segment 1 1  
Customers average payment term 30 days    
Distributors average payment term 60 days    
Number of distribution and license agreements | agreement 3    
Net revenue $ 18,914 $ 22,676  
Concentrate Products      
Revenue Recognition [Line Items]      
Net revenue 18,589 $ 22,665  
Da Vita Healthcare Partners Inc | Concentrate Products      
Revenue Recognition [Line Items]      
Net revenue 900    
Sun Pharma, Jeil Pharma, and Drogsan Pharma      
Revenue Recognition [Line Items]      
Deferred revenue $ 300    
Da Vita Healthcare Partners Inc | Revenue Benchmark | Customer Concentration Risk      
Revenue Recognition [Line Items]      
Customer concentration, percentage 27.00% 44.00%  
Da Vita Healthcare Partners Inc | Accounts Receivable | Customer Concentration Risk      
Revenue Recognition [Line Items]      
Customer concentration, percentage 17.00%   20.00%
Nipro Medical Corporation | Accounts Receivable | Customer Concentration Risk      
Revenue Recognition [Line Items]      
Customer concentration, percentage 16.00%    
Fresenius Medical Care North America | Revenue Benchmark | Customer Concentration Risk      
Revenue Recognition [Line Items]      
Customer concentration, percentage 10.00% 7.00%  
Fresenius Medical Care North America | Accounts Receivable | Customer Concentration Risk      
Revenue Recognition [Line Items]      
Customer concentration, percentage 10.00%